influvac tetra 15 µg/0.5 ml+ 15 µg/0.5 ml+ 15 µg/0.5 ml+ 15 µg/0.5 ml suspenzija za injekciju u napunjenoj šprici
viatris bh d.o.o. - influenca, inaktivisana, fragmentisani virus ili površinski antigen - suspenzija za injekciju u napunjenoj šprici - 15 µg/0.5 ml+ 15 µg/0.5 ml+ 15 µg/0.5 ml+ 15 µg/0.5 ml - 0,5 ml suspenzijeza injekciju sadrži: a/brisbane/02/2018 (h1n1)pdm09– sličan soj (a/brisbane/02/2018, ivr190) 15 mikrograma ha** a/kansas/14/2017 (h3n2) – sličan soj (a/kansas/14/2017, nymc x327) 15 mikrograma ha** b/colorado/06/2017 – sličan soj (b/victoria/2/87 soj) (b/maryland/15/2016, nymc bx69a) 15 mikrograma ha** b/phuket/3073/2013 – sličan soj (b/yamagata/16/88 soj) (b/phuket/3073/2013, divlji tip) 15 mikrograma ha**
veklury
gilead sciences ireland uc - remdesivir - covid-19 virus infection - veklury is indicated for the treatment of coronavirus disease 2019 (covid 19) in:adults and paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment)adults and paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19.
sarclisa
sanofi winthrop industrie - isatuximab - multipli mijelom - antineoplastična sredstva - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.
unasterid 0,5 mg/1 kapsula kapsula, meka
doo ˝farmacija 2011˝ bihać - dutasterid - kapsula, meka - 0,5 mg/1 kapsula - jedna kapsula, meka sadrži: 0,5 mg dutasterida
cebopim 1 g/1 bočica prašak za rastvor za injekciju
doo ˝farmacija 2011˝ bihać - cefepim - prašak za rastvor za injekciju - 1 g/1 bočica - jedna bočica sadrži 1g cefepima (u obliku cefepim dihlorid monohidrata)
aristinc 400 mg/200 ml rastvor za infuziju
doo ˝farmacija 2011˝ bihać - ciprofloksacin - rastvor za infuziju - 400 mg/200 ml - 1 ml rastvora za infuziju sadrži: 2 mg ciprofloksacina
aristinc 200 mg/100 ml rastvor za infuziju
doo ˝farmacija 2011˝ bihać - ciprofloksacin - rastvor za infuziju - 200 mg/100 ml - 1 ml rastvora za infuziju sadrži:2 mg ciprofloksacina
vankar 500 500 mg/1 bočica prašak za rastvor za infuziju
doo ˝farmacija 2011˝ bihać - vankomicin - prašak za rastvor za infuziju - 500 mg/1 bočica - 1 bočica sa praškom za rastvor za infuziju sadrži 500 mg vankomicina (u obliku vankomicinhidrohlorida)
paxlovid
pfizer europe ma eeig - nirmatrelvir, ritonavir - covid-19 virus infection - paxlovid is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe covid 19.